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Selective motoneurons (MNs) degeneration in the brain stem, hypoglossal motoneurons
(HMNs), and the spinal cord resulting in patients paralysis and eventual death
are prominent features of amyotrophic lateral sclerosis (ALS). Previous studies
have suggested that mitochondrial respiratory impairment, low Ca2+ buffering and
homeostasis and excitotoxicity are the pathological phenotypes found in mice, and
cell culture models of familial ALS (fALS) linked with Cu/Zn-superoxide dismutase 1
(SOD1) mutation. In our study, we aimed to understand the impact of riluzole and
melatonin on excitotoxicity, neuronal protection and Ca2+ signaling in individual HMNs
ex vivo in symptomatic adult ALS mouse brain stem slice preparations and in WT
and SOD1-G93A transfected SH-SY5Y neuroblastoma cell line using fluorescence
microscopy, calcium imaging with high speed charged coupled device camera, together
with immunohistochemistry, cell survival assay and histology. In our experiments, riluzole
but not melatonin ameliorates MNs degeneration and moderately inhibit excitotoxicity
and cell death in SH-SY5YWT or SH-SY5YG93A cell lines induced by complex IV
blocker sodium azide. In brain stem slice preparations, riluzole significantly inhibit HMNs
cell death induced by inhibiting the mitochondrial electron transport chain by Na-
azide. In the HMNs of brainstem slice prepared from adult (14–15 weeks) WT, and
corresponding symptomatic SOD1G93A mice, we measured the effect of riluzole and
melatonin on [Ca2+]i using fura-2 AM ratiometric calcium imaging in individual MNs.
Riluzole caused a significant decrease in [Ca2+]i transients and reversibly inhibited
[Ca2+]i transients in Fura-2 AM loaded HMNs exposed to Na-azide in adult symptomatic
SOD1G93A mice. On the contrary, melatonin failed to show similar effects in the
HMNs of WT and SOD1G93A mice. Intrinsic nicotinamide adenine dinucleotide (NADH)
fluorescence, an indicator of mitochondrial metabolism and health in MNs, showed
enhanced intrinsic NADH fluorescence in HMNs in presence of riluzole when respiratory
chain activity was inhibited by Na-azide. Riluzole’s inhibition of excitability and Ca2+
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signaling may be due to its multiple effects on cellular function of mitochondria.
Therefore formulating a drug therapy to stabilize mitochondria-related signaling
pathways using riluzole might be a valuable approach for cell death protection in ALS.
Taken together, the pharmacological profiles of the riluzole and melatonin strengthen
the case that riluzole indeed can be used as a therapeutic agent in ALS whereas claims
of the efficacy of melatonin alone need further investigation as it fail to show significant
neuroprotection efficacy.
Keywords: ALS, SOD1G93A, riluzole, melatonin, mitochondria, excitotoxicity, cell death, Ca2+ signaling
INTRODUCTION
One of the hallmarks of ALS is extensive loss of MNs in the brain
stem, hypoglossal nucleus, facial nucleus, and the spinal cord
(Spalloni et al., 2004; Von Lewinski and Keller, 2005a,b; Spiller
et al., 2016). Evidence is increasing that Ca2+ dysregulation
and mitochondrial dysfunction is involved in the SOD1 G93A
(SOD1G93A) mouse model (Kong and Xu, 1998; Jaiswal and
Keller, 2009; Jaiswal, 2013, 2014; Chang and Martin, 2016;
Paine and Jaiswal, 2016). The precise mechanisms leading to
the selective loss of MNs in ALS patients as well as a possible
determinant of selective MNs death in transgenic (Tg) mouse
models of this disorder remain elusive. Many findings indicated
two important characteristic features of this disorder: (1) the
presence of low level of calcium binding proteins in combination
with high buffering capacity in affected MNs (Alexianu et al.,
1994; Kaal et al., 1998; Laslo et al., 2000; Jaiswal et al., 2009;
Jaiswal, 2014) and (2) involvement of AMPA receptors (AMPAR;
Rothstein, 1995; Van Den Bosch et al., 2000; Udagawa et al., 2015;
Chang and Martin, 2016).
Riluzole is the only FDA-approved neuroprotective
compound used in clinics for the treatment of ALS/MN disease
(Bensimon et al., 1994; Jehle et al., 2000; Obinu et al., 2002;
Gutierrez et al., 2016). Riluzole’s neuroprotective properties
appear to arise from both presynaptic and postsynaptic
mechanisms for attenuating glutamatergic neurotransmission,
allowing riluzole to act as an antiglutamate drug (Bryson
et al., 1996; Doble, 1996; Wokke, 1996; Geevasinga et al.,
2016) and it block depolarization-evoked Ca2+ transients in
MNs (Hubert et al., 1998). Moreover, many groups reported
that riluzole works by inhibiting Na+ channels (Stefani et al.,
1997; Yokoo et al., 1998; Zona et al., 1998; Geevasinga et al.,
2016), inhibits Cl− channels (Bausch and Roy, 1996), increases
glutamate uptake and has an impact on glutamate receptors
(Azbill et al., 2000) and inhibits GABA reuptake (Kretschmer
et al., 1998). Additionally, riluzole was shown to attenuate
Abbreviations: aCFS, artificial cerebrospinal fluid; ALS, amyotrophic lateral
sclerosis; AM, acetoxy methyl ester; CCD, charge coupled device; CRAC, Ca2+
release-activated Ca2+; DMSO, dimethyl sulfoxide; ER, endoplasmic reticulum;
ETC, electron transport chain; F, fluorescence; fALS, familial amyotrophic
lateral sclerosis; HMNs, hypoglossal motoneurons; MNs, motor neurons; NADH,
nicotinamide adenine dinucleotide; ROI, regions of interest; ROS, reactive oxygen
species; SD, standard deviation; SEM, standard error of mean; SOD1, superoxide
dismutase 1; WT, wild-type; [Ca2+]i, cytosolic calcium; [Ca2+]mito, mitochondrial
calcium;19m, mitochondrial membrane potential.
neurotoxicity in tissue preparations and an animal model as
well (Lang-Lazdunski et al., 2000; Mu et al., 2000). Earlier it was
shown that an increase in [Ca2+]i is a critical messenger for
diverse pathophysiological events or in case of ALS and other
neurodegenerative disorder and generally abnormal [Ca2+]i
increases are cytotoxic (Bootman et al., 1993; Berridge, 1997;
Budd, 1998). Riluzole is known to block persistent sodium
currents and earlier it was shown that riluzole block the Trpm4
(pore-forming subunits of Sur1-regulated NCCa-ATP channels),
a key mechanism for the beneficial effect of riluzole in spinal cord
injury (Simard et al., 2012). Moreover, Trpm4 is a Ca2+-activated
cation channel that were found to expressed at higher levels in
Th2 cells and inhibition of Trpm4 expression increased Ca2+
influx (Weber et al., 2010) via Ca2+ release-activated Ca2+
(CRAC) channel and Ca2+-activated K+ current (Kca) channels
(Dolmetsch and Lewis, 1994). More recently it was discovered
that Ca2+ influx and oscillations are also regulated by Trpm4 in
Jurkat T cells (Launay et al., 2004). Work from all these previous
studies indicated three compelling reasons for the beneficial
effects of riluzole (i) block of persistent Na+ currents (molecular
mechanism not known), (ii) inhibition of glutamatergic signaling
pathways and (iii) an indirect neurotrophic effect. In spite of all
these discoveries, it is not precisely established yet the precise
mechanism through which riluzole acts on ion channels either
directly or through second messenger signaling cascades, which
attenuate ion influx-induced neuronal death.
Another effective cellular antioxidant known to be efficiently
scavenging toxic free radicals, ROS and associated reactants is
Melatonin (Jou et al., 2004; Reiter et al., 2016). Recent findings in
which azides/CN-induced cell death via blocking complex IV of
the mitochondrial ETC is reversed by melatonin and prevention
of mitochondrial damage induced by ruthenium red (inhibits
the mitochondrial Ca2+ uniporter for Ca2+ uptake), suggest
that melatonin may act at the mitochondrial subcellular level
and reduce ROS induced damage (Yamamoto and Tang, 1996;
Martin et al., 2000). Furthermore, administrations of melatonin
repair mitochondrial functioning in aging mice and shown to
be neuroprotective in in vitro models of Alzheimer’s disease
(Pappolla et al., 1997; Okatani et al., 2003).
Collectively, these results demonstrate the protective effects of
riluzole and melatonin in neurodegenerative diseases involving
mitochondrial dysfunction. However, we do not know if
the therapeutic effects of these drugs in various pre-clinical
mitochondria related neurodegenerative diseases also effective
in ALS. Moreover, since mitochondrial ROS-induced cell death
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and excitotoxicity play a prominent role in ALS disease, specific
neuroprotection mechanisms of riluzole and melatonin at the
mitochondrial sub cellular level involving excitotxicity and Ca2+
signaling need to be further investigated. In this context, we
determine whether treatment with riluzole or melatonin could
attenuate sodium-azide (Na-azide) induced ROS and eventually
cell death. Additionally, we investigated the impact of riluzole
and melatonin on vulnerable HMNs of adult symptomatic
SOD1G93A mice and corresponding wild type (WT) littermates.
Imaging experiments were performed on adult brain stem slices
where mitochondrial function of HMNs was disturbed by a
bath application of 3 mM Na-azide, which inhibits complex
IV and thereby disturbs mitochondrial metabolism. Riluzole
and melatonin protection studies were similarly designed where
application of sodium azide was performed because of, (1) its
quick and reversible action, and (2) In both sALS and fALS
a decrease in mitochondrial complex IV observed (Nowicky
and Duchen, 1998; Menzies et al., 2002). The cell death, cell
survival and Ca2+ signals were characterized and evaluated in the
presence or absence of drugs.
We found that riluzole moderately ameliorates MN
degeneration, inhibits excitotoxicity and mildly and reversibly
inhibits Ca2+ signaling. However, melatonin fails to show
significant MN protection and significant impact on Ca2+
signaling both in adult WT and corresponding SOD1G93A mice
as well as in cell culture model of ALS. We anticipate that this
experimental system can be used to screen the drugs targets
either alone or in combination of drug cocktails that can be used
for large-scale compound screening.
MATERIALS AND METHODS
SH-SY5YWT and SH-SY5YG93A
Neuroblastoma Cell Lines
SH-SY5Y human neuroblastoma cell line transfected with either
WT or G93A mutant linked with fALS were routinely cultured
in growth medium and were used as a valid and robust in vitro
system to investigate the cellular excitotoxicity and mitochondria
mediated alterations associated with SOD1-G93A mutations
(Carri et al., 1997; Goos et al., 2007; Jaiswal et al., 2009).
Detail descriptions about the transfection strategy, cell culture
maintenance, cell culture growth medium and procedures are
described earlier (Jaiswal et al., 2009).
Measurement of Cell Viability Using
Mitochondrial Toxin Sodium Azide and
Neuroprotection by Riluzole and
Melatonin
Toxicity of Na-azide induced mitochondrial inhibition and
thereby cell death assay in SH-SY5YWT and SH-SY5YG93A was
done using bright field microscopy, hematoxylin and eosin
(H&E) histochemistry and WST-1 assay. Neuroprotection study
was done using similar method. SH-SY5YWT and SH-SY5YG93A
transfected cells on glass coverslips were treated for 3 min
(acute), 30 min (moderate) and 60 min (chronic) exposure with
3 mM Na-azide (60 min data not shown), cells were fixed with
4% paraformaldehyde (PFA), dehydrated through water/ethanol
and histolene and then stained with Meyer’s hemalum reagent
(1:1 in H2O). While choosing the Na-azide concentrations we
followed the previous literature and accordingly we selected
three different Na-azide concentrations, 1, 3, and 10 mM for
cytotoxicity induced cell death assays and neuroprotection study
(Hunter et al., 1959; Harvey et al., 1999). Concentration of 1 mM
Na-azide not always leads to swelling of mitochondria for acute
(3 min) exposure. Also shown by other groups at 0.1 mM or less
than 2 mM sodium cyanide (NaCN) was not always adequate
to prevent completely spontaneous swelling or swelling induced
by low concentrations of phosphate (Hunter et al., 1959; Harvey
et al., 1999). Higher concentration, e.g., 10 mM Na-azide might
react with components other than cytochrome oxidase, therefore
based on our pilot toxicity experiments and previous literature,
we have chosen 3 mM Na-azide concentration suitable for our
acute toxicity (3 min exposure) and neuroprotection assays.
To study the differences in impact of Na-azide–induced cell
death and neuroprotection mediated by riluzole and melatonin,
SY5YWT and SH-SY5YG93A cells at a density of 105 cells/cm2
were seeded into 24-well plates. SH-SY5YWT and SH-SY5YG93A
cells were exposed to culture medium with 3 mM Na-azide for
3 min (acute), 30 and 60 min (chronic). After 3, 30, and 60 min
(60 min data not shown) of exposure, cell photomicrograph
was acquired using brightfield microscope. Furthermore, for
neuroprotection assay by riluzole and melatonin, both cell lines
were exposed to DMEM growth medium with 3 mM Na-
azide+100 µM riluzole or 3 mM Na-azide+100 µM melatonin
for 3 min (acute). After rinsing the cover slips twice with water,
cover slips were dehydrated and Vectashield Medium (Vector
Laboratories, Burlingame, CA, USA) was used for mounting the
cover slips.
To further investigate the impact of Na-azide exposure on cell
viability and neuroprotection by riluzole and melatonin, cells at
a density of 105 cells/cm2 in 24-well plates were treated with
culture medium or medium containing 3 mM Na-azide final
concentration. After 3, 30, and 60 min (60 min data not shown)
of incubation with 3 mM Na-azide, WST-1 cell proliferation
reagent (Roche Applied Science, Mannheim, Germany) was used
to determine cell viability. For neuroprotection, similar WST-1
assay were done using 3 mM Na-azide+100µM riluzole or 3 mM
Na-azide+100 µM melatonin. The WST-1 assay is comprises
a cleavage of the tetrazolium salt by healthy mitochondria to
soluble orange formazan, by the enzyme succinate dehydrogenase
present in the ETS of healthy mitochondria. The formazan dye
formed after incubation of cells with WST-1 for 2 h was quantified
by measuring the absorbance at 490 nm using the Genios
multiplate reader (Tecan, Crailsheim, Germany) and correlates
with the total number of metabolically viable cells.
Animals and Genotyping
Superoxide dismutase 1G93A Tg 1Gur (Fast Line) mice strain
is considered a well-established animal model for human ALS.
This mice strain acquired from the Jackson Laboratory (Bar
Harbor, ME, USA) and in-house breeding was carried out in our
animal facility. The SOD1G93A Tg mouse develop paralysis in the
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limb and eventually dies at 4–5 months of age due to the loss
of MNs in the brain stem, HMNs, FMNs, and the spinal cord
whereas WT littermates were unaffected. The Tg mouse carries
a variation of the human mutant G93A-SOD1 gene in which at
position 93 glycine is substituted by alanine (Gurney et al., 1994).
Breeding and genotyping procedures were adapted from Hoyaux
et al. (2000; for further details also see Jaiswal and Keller, 2009).
Animal breeding and experimental procedures were approved
and carried out in accordance with the guidelines of the ethics
committee of the Medical Faculty of Georg-August University,
Göttingen, Germany.
Preparation of Acute Brain Stem Slices
from Adult SOD1G93A/WT Mice
Littermates
Mice were anesthetized until the paw withdrawal reflex
disappeared in a chamber containing an ether vapor-enriched
atmosphere and immediately sacrificed. Mice brains were quickly
removed and then put in 4◦C ice-cold aCSF. Transverse 250 µm
thick acute brain stem slices were prepared from the 14–15 weeks
old WT and symptomatic SOD1G93A mice in late stage of
motor dysfunction according to the procedures described earlier
(Ladewig and Keller, 2000; Jaiswal and Keller, 2009) using a
vibroslicer (Leika VT 1000S, Göttingen, Germany). Selectively
vulnerable brain stem HMNs (Nuc. hypoglossus; XII) region were
visually identified by their location nearby to the IV ventricle
during the brain stem slice preparations transversely (Figure 3).
To achieve maximum oxygen supply to slices, aCSF (in mM:
NaCl 118, KCl 3, NaH2PO4 1, CaCl2 1.5, MgCl2 1, NaHCO3
25, glucose 20; pH 7.4; 320 mOsm) was constantly simmered
with a mixture of 95% O2 and 5% CO2 (carbogen). An essential
requirement for the microfluorometric measurements was the
preservation of MNs in adult slices near to the slice surface in
a physiologically viable and intact condition. This challenging
requirement for Ca2+ imaging in MNs was accomplished by
reducing mechanical tissue disturbances during the thick adult
brain slice preparations, slice cutting at 4◦C temperature and
regular maximum oxygen delivery to keep metabolic conditions
optimum for cells viability (For details, see Jaiswal and Keller,
2009). Slices were kept at ∼27◦C in continuous carbogen-
bubbled aCSF solution at pH 7·4 for 30 min and then let
it cool down to room temperature (RT, ∼20–21◦C) prior to
dye loading. Unless indicated otherwise, all experiments were
performed at RT.
Charge Coupled Device (CCD) Fast
Optical Imaging
Intracellular calcium [Ca2+]i fluorescence measurement were
achieved using an optical recording system including an upright
Axioscope microscope (Zeiss, Göttingen, Germany) equipped
with a computer-operated monochromator (TILL Photonics,
Martinsried, Germany) built on a galvanometric scanner
(Polychrome II, TILL Photonics, Martinsried, Germany). Briefly,
a modified version of the CCD camera system (TILL Photonics,
Planegg, Germany) and Achroplan W 63×, 0.9W objective were
used to collect fluorescent signal changes in defined “regions of
interest” (ROIs) in cell soma. Fluorescence signals changes were
digitized using a 12-bit CCD camera (PCO, Kelheim, Germany),
binning of which was put to 4 × 4, with a sampling rate
between 3 and 13 Hz using TILL Vision Software (TILL Vision
Software V3.3, TILL Photonics, Germany). Dichroic mirror with
mid reflection at 425 nm was used for Fura-2 AM calcium dye
(Invitrogen, Carlsbad, CA, USA) to direct the emitted light.
To achieve the ratiometric calcium imaging, swapping between
wavelengths (360 and 390 nm) was achieved in ∼3 ms, thereby
allowing fast ratiometric Ca2+ measurements.
Microfluorometric Ca2+ Measurements
in SH-SY5Y Transfected Cells and HMNs
from WT and SOD1G93A Brain Stem Slice
Preparations
WT (SH-SY5YWT) and SOD1 (SH-SY5YG93A) transfected cell
layers on cover slips were stained with membrane-permeable
Fura-2 AM (Kd ∼ 0.2 µM) dye by incubating with RPMI-
1640 medium having 10% FCS (Invitrogen, Carlsbad, CA,
USA) and 0.846 mM Ca2+ (5 µM Fura-2 AM dissolved in
DMSO containing 10% pluronic acid for 30 min at 37◦C and
continuous bubbled with 95% O2 and 5% CO2). After the dye
incubation cells were washed with RPMI and incubated in culture
medium for ∼20 min at 37◦C to permit de-esterification of dye.
Baseline [Ca2+]i were measured in transfected cells 2–5 days in
culture. Chemical induction of Ca2+ measurements were done
by incubating the cells for 3 min with 3 mM Na-azide and effects
of 100 µM riluzole and 100 µM melatonin were measured by
inhibition of Ca2+ with similar measurements (data not shown).
In HMNS of brain stem slice, calcium signals were measured
by defining appropriate ROIs of MN somas as previously
described (Lips and Keller, 1998). [Ca2+]i signals were monitored
by bath-loading of the brain stem slices with 5 µM final dye
concentration of Fura-2 AM for 40 min at 27◦C with continuous
carbogen bubble (5% CO2 and 95% O2). After the dye incubation,
prior to onset of imaging slices were washed with aCSF and
incubated another 30 min in aCSF for de-esterification of Fura-2
AM. Excitation of Fura-2 was done alternately at 360 and 390 nm
by UV light and emitted light was directed to a dichroic mirror
having mid-reflection at 425 nm and filtered by a band pass filter
of 505–530 nm (Zeiss, Goettingen, Germany) using a computer-
controlled monochromator. Changes in [Ca2+]i are denoted
as variations in Fura-2 ratio (F/F0) where F = fluorescence
at different time points of experiment and F0 = baseline
fluorescence value before drug/chemical applications (for details
see Jaiswal and Keller, 2009). Further calculations and analysis
of [Ca2+]i signals were performed oﬄine using IGOR Pro
(Wavemetrics, Lake Oswego, OR, USA) and OriginPro 6.0
(OriginLab Corporation, Northampton, MA, USA) Software.
Intrinsic nicotinamide adenine
dinucleotide (NADH) Fluorescence
The metabolic state of HMNs from SOD1G93A mice in the
presence and absence of 100 µm riluzole was monitored
by measuring and monitoring intrinsic nicotinamide adenine
dinucleotide (NADH) fluorescence of HMNs in the slice
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preparations using a high-speed CCD camera. Briefly, NAD(P)H
excitation at 360 nm was carried via a computer-controlled
monochromator ((TILL Photonics, Martinsried, Germany)
reflected onto the surface of the slice using dichroic mirror
(400 nm, Zeiss, Goettingen, Germany). The hypoglossal nucleus
was easily recognized by a high level of intrinsic fluorescence.
Fluorescence emission was collected by using a CCD camera
(TILL Photonics, Planegg, Germany). All experiments used a
410 nm LP filter between the dichroic mirror and camera to
maximize light capture. Imaging was performed after focusing
onto the surface of slices in hypoglossal area using 63× (0.9
NA) Achroplan water objective (Zeiss, Göttingen, Germany) and
collected by a 12-bit CCD camera (PCO, Kelheim, Germany)
described earlier. Calculations and analysis of NAD(P)H signals
were performed oﬄine after the experiment using IGOR Pro
(Wavemetrics, Lake Oswego, OR, USA) and OriginPro 6.0
(OriginLab Corporation, Northampton, MA, USA) Software.
Chemical Reagents
Fura-2 AM dye (50mg/vial) was purchased from Invitrogen
(Carlsbad, CA, USA) and dissolved in 50 µL DMSO containing
20% Pluronic F-127 to a concentration of 1 mM. Na-azide,
riluzole, melatonin and all other chemicals were purchased from
Sigma–Aldrich (St. Louis, MO, USA). To prepare the stock
solutions, riluzole and melatonin were dissolved in 100% ethanol
to make 10 mM stock solutions and all the time kept at 4◦C to
avoid ethanol evaporation. Na-azide was dissolved in distilled
water. To keep cells viable drug solutions when mixed in the
perfusate always simmered with carbogen (95% O2, 5% CO2)
during the experiments.
Statistical Analysis
SH-SY5YWT and SH-SY5YG93A transfected cells attached with
cover slip was used for single experiments and replicate in
five separate experiments (five field of view) for each condition
in cell viability assay (cell survival/death) and seven separate
experiments (seven field of view for each cover slides for SH-
SY5YWT and SH-SY5YG93A) for neuroprotection assay. All slices
were used for a sole experiment and 5–6 HMNs taken from
each slice in Fura-2 calcium imaging data experiments. 2–3 slices
were used per mouse and 5–6 HMNs selected from each slice
for bar graph presentation. In slice experiments, bar diagram
represents 12 imaging experiments recorded from 12 separate
slices obtained from 5 WT mice and 10 imaging experiments
recorded from 10 slices obtained from 5 SOD1G93A mice in
acute Na-azide experiments. In case of riluzole experiments,
bar diagram represent 14 imaging experiments recorded from
14 separate slices obtained from 6 WT mice and 13 imaging
experiments recorded from 13 slices obtained from 6 SOD1G93A
mice. In case of NADH fluorescence imaging, 5–6 cells from
slice for five separate experiments for each condition from five
different mice of same genotypes was used for bar diagram
representation. Values in the text and error bars in experimental
figures are represented as mean ± SD. Significance for all the
in vitro assay, slice imaging and pharmacological intervention
was calculated using the two-tailed unpaired student t-test and
a p-value < 0.05 was considered statistically significant. One-
way analysis of variance (ANOVA) with Bonferroni’s method was
used as the post hoc test used to recognize statistically significant
Na-azide effects, and neuroprotection effects of riluzole and
melatonin exposed cells as compared with controls with in
groups.
RESULTS
Cell Death Assessment by Inhibition of
Mitochondria and Neuroprotective
Actions of Riluzole and Melatonin
against Sodium Azide-Induced Cell
Death in In vitro SH-SY5Y Cell Culture
Model of ALS
We utilized differentiated SH-SY5YWT and SH-SY5YG93A cells
used previously to generate WT and SOD1G93A cell culture model
of ALS (Jaiswal et al., 2009). Cell death, cell viability and anti-
aggregate formation were assessed using bright field microscopy,
immunocytochemistry and WST-1 cell proliferation assay
(Figures 1 and 2). SH-SY5YG93A cells showed slightly higher
levels of cell death compared to SH-SY5YWT after 3 and 30 min
(Figures 1A–Da–c and 2A) exposure to mitochondrial toxin Na-
azide (Figures 1A–Da–c and 2A). A similar pattern was observed
while investigating the apoptosis and aggregation assessed by
bright field microscopy demonstrating typical apoptotic
morphology, e.g., condensation/fragmentation of nuclear
material and elongation of cell size and cell membranes. Cells
displaying fragmentation of nuclear materials (pyknosis)/cell
membrane elongation were classified as apoptotic and showed
aggregates formation with both cell lines after incubation
for 30 and 60 min (Figures 1Aa–c,Ca–c; data not shown for
60 min exposure) but not with acute 3 min (acute) induction
(Figures 1Aa–c,Ca–c). We have not quantified the cell numbers
after 30 and 60 min exposure to Na-azide due to lump formation
after 30 min exposure and inability to separate each cells with
in aggregates and almost complete cell death 60 min after the
inhibition of mitochondria by Na-azide (Figures 1Ac,Cc).
Cell survival/death was assessed by H&E staining and WST-1
test. Cell count for H&E staining for both SH-SY5YWT and
SH-SY5YG93A cells treated with Na-azide for 3 min (77.0 ± 4.7
for WT and 71.5 ± 6.1 for SOD1G93A) and 30 min (59.2 ± 5.8
for WT and 54.0 ± 5.5 for SOD1G93A) were significantly lower
compared to untreated cells with Na-azide (114.5 ± 2.8 for WT
and 107.0± 5.1 for SOD1G93A; Figures 1A–Da–c and 2A; N = 5;
∗∗∗P < 0.001, ∗∗P < 0.005, Students two sample t-test, Table 1).
It was previously reported by several groups that riluzole
and melatonin ameliorates ALS progression in SOD1G93A mouse
model and extend morbidity of hALS patients. We next
attempted to determine whether riluzole and melatonin confers
neuroprotection and ameliorate cell death in ALS cell culture
model and if yes at what extent. Previously it was shown that
riluzole up to 10 µM have no effect on cell survival in DA
neurons and SH-SY5Y cells. However, concentrations greater
than 50µM have a remarkable effect on cell survival (Storch et al.,
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FIGURE 1 | Motor neurons cell death assessment using mitochondrial toxin Sodium azide and neuroprotection assay to access efficacy of riluzole
and melatonin. (A) Photomicrograph of bright field images of differentiated SH-SY5YWT cells exposed to growth medium DMEM (a), DMEM+3 mM Na-azide for
3 min (b), DMEM+3 mM Na-azide for 30 min (c), DMEM+3 mM Na-azide+3 mM riluzole for 3 min (d), and DMEM+3 mM Na-azide+3 mM melatonin for 3 min (e).
Note the decrease in cell density after Na-azide exposure, which is ameliorated in presence of riluzole, but not melatonin. (B) H&E staining showed a substantially
higher density of living SH-SY5YWT cells exposed to DMEM (a) compared to SH-SY5YWT cells exposed to DMEM+3 mM Na-azide for 3 min (acute, b) and 30 min
(chronic, c). Note the shrinkage, clustering, and reductions in cell number of severely damaged/dead SH-SY5YWT neuroblastoma cells in b and c. H&E staining
showed 3 min acute exposure of 3 mM Na-azide induced cell death is partially ameliorated in the presence of 3 mM riluzole (d), but not in the presence of 3 mM
melatonin (e). (C) Bright field images of differentiated SH-SY5YG93A cells exposed to DMEM (a), DMEM+3 mM Na-azide for 3 min (b), DMEM+3 mM Na-azide for
30 min (c), DMEM+3 mM Na-azide+3 mM riluzole for 3 min (d), and DMEM+3 mM Na-azide+3 mM melatonin for 3 min (e). Note the decrease in cell density in
presence of 3 mM (acute) and 30 min (chronic) Na-azide exposure. Note the increase in cell density of SH-SY5YWT cells compared to SH-SY5YG93A cells in
presence of 3 mM riluzole suggesting greater susceptibility of SH-SY5YG93A to mitochondrial-induced damage. (D) H&E staining showed a similar substantially
higher density of living SH-SY5YG93A cells like SH-SY5YWT cells exposed to DMEM (a) compared to cells exposed to 3 min (acute, b) and 30 min (chronic, c)
exposure with 3 mM Na-azide. Cell death of H&E stained SH-SY5YG93A cells in presence of 3 mM Na-azide exposure is partially ameliorated in presence of 3 mM
riluzole (d), but not in presence of 3 mM melatonin exposure (e). Scale bar for (A) and (C) = 20 µm and (B) and (D) = 100 µm.
2000); therefore, here we used 100 µM riluzole and melatonin
exposure with superfusate and evaluate the protective effects of
riluzole on cell survival in SH-SY5YWT and SH-SY5YG93A cells
in vitro (Figures 1A–Dd,e and 2A). Our findings show that the
acute inhibition of mitochondrial metabolism and function and
thereby cell death by Na-azide is ameliorated by riluzole but there
is no significant effects of melatonin in both SH-SY5YWT and SH-
SY5YG93A cells (Figures 1A–Dd,e and 2A). The average number
of H&E positive cells in a given field of view (seven field of view)
after the treatment of 100 µM riluzole to SH-SY5YWT and SH-
SY5YG93A cells is significantly higher (Figure 2A; 110.0± 7.8 for
WT and 101.2 ± 6.7 for SOD1G93A) compared to non-treated
cells stimulated with 3 mM Na-azide (Figure 2A; 77.0 ± 4.7
for WT and 71.5 ± 6.1 for SOD1G93A; for riluzole treated
and non-treated cells; ∗∗P < 0.005, Students two sample t-test;
Table 1). In addition to decreasing the cell death, riluzole had
significant protective effects on the neuritis, fine cell processes
and cell membrane integrity being preserve from mitochondrial
inhibition and the effect was most pronounced in SH-SY5YWT
compared to SH-SY5YG93A cells (Figures 1Ad–Dd). However,
impact of 100 µM melatonin treatment on Na-azide induced
inhibition of mitochondria is not significantly different then non-
treated cells in both SH-SY5YWT and SH-SY5YG93A cells though
there are minor increase in cell count of WT and SOD1G93A cells
(Figures 1A–De and 2A; 87.2 ± 7.0 for WT and 82.5 ± 5.3 for
SOD1G93A, Table 1).
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FIGURE 2 | Riluzole but not melatonin stimulation increased cells survival and neuroprotective against sodium azide induced mitochondrial ETC
blockade both in SH-SY5YWT and SH-SY5YG93A cells. (A) Live cell count of SH-SY5YWT (gray bar) and SH-SY5YG93A (red bar) neuroblastoma cells after
incubation with DMEM, DMEM+3 mM Na-azide for 3 min, DMEM+3 mM Na-azide for 30 min, DMEM+3 mM Na-azide+3 mM riluzole for 3 min and DMEM+3 mM
Na-azide+3 mM melatonin for 3 min (average of cell counts for seven field of view in each conditions). Please note the significant difference between riluzole-treated
and non-treated SH-SY5YWT and SH-SY5YG93A cells exposed to Na-azide (p < 0.005). (B) Toxicity of Na-azide for SH-SY5YWT and SH-SY5YG93A cells was
measured using the WST-1 cell viability test in presence of DMEM, DMEM+3 mM Na-azide for 3 min, DMEM+3 mM Na-azide for 30 min, DMEM+3 mM
Na-azide+3 mM riluzole for 3 min and DMEM+3 mM Na-azide+3 mM melatonin for 3 min. SH-SY5YWT and SH-SY5YG93A cells were more vulnerable to the action
of Na-azide in absence of riluzole compared to 3 mM riluzole presence in DMEM growth medium (p < 0.01). Data are expressed as the mean ± SEM. ∗∗∗P < 0.005,
∗∗P < 0.01, ∗P < 0.05 two-tailed unpaired student t-test.
TABLE 1 | Cell count of H&E staining for SH-SY5YWT and SH-SY5YG93A cells treated with sodium azide in presence and absence of riluzole and
melatonin.
Treatment SH-SY5YWT SH-SY5YG93A P-value
DMEM, 3 min 114.5 ± 2.84 107 ± 5.01 0.001
DMEM+3 mMNa-azide, 3 min 77 ± 4.79 71.5 ± 6.19 0.005
DMEM+3 mM Na-azide, 30 min 59.25 ± 5.83 54 ± 5.59 0.001
DMEM+3 mM Na-azide+100 µM Riluzole, 3 min 110 ± 7.85 101.25 ± 6.71 0.005
DMEM+3 mM Na-azide+100 µM Melatonin, 3 min 87.25 ± 7.09 82.5 ± 5.3619 n.s.
Cell viability assessed by WST-1 assay showed significant dose
dependent ROS-induced mitochondrial toxicity and cell death.
Cell viability of SH-SY5YWT and SH-SY5YG93A cells in presence
of Na-azide for 3 and 30 min leads to a decrease in cell survival
(75.0 ± 3.4 and 61.2 ± 6.1% for 3 and 30 min incubation,
respectively, for WT; Figure 2B) and were significantly not
different with SOD1G93A cells (73.5 ± 6.2 and 54.0 ± 8.4%
for 3 and 30 min incubation, respectively; Figure 2B; Table 2).
However, cell viability for both WT and SOD1G93A treated
cells were much lower and significantly different compared to
untreated cells without Na-azide toxicity (100 ± 3.4% for WT
and 91 ± 8.6% for SOD1G93A; Figures 1A–Da–c and 2A; N = 5;
∗∗∗P < 0.001, Students two sample t-test; Table 2). Similarly %
of SH-SY5YWT and SH-SY5YG93A viable cells after the treatment
of 100 µM riluzole is significantly higher (Figure 2B; 91.0 ± 4.5
for WT and 88.2 ± 5.2 for SOD1G93A; Table 2) compared
to non-treated cells stimulated with 3mM Na-azide for 3 min
(Figure 2A; 75 ± 6.3% for WT and 73.5 ± 6.3% for SOD1G93A;
∗∗P < 0.01, Students two sample t-test; Table 2). There is no
significant increase in cell survival after melatonin treatment
(Figure 2B; 80.2 ± 5.3 for WT and 78.5 ± 4.2 for SOD1G93A;
Table 2).
Impact of Riluzole on Sodium
Azide-Induced Mitochondrial [Ca2+]i
Release and Excitotoxicity
To test further the efficacy of riluzole on Na+-azide induced
mitochondrial Ca2+ signaling, Fura-2 AM stained HMNs of
brain stem slices were exposed to Na-azide in presence and
absence of 100 µM riluzole. Sketch diagram of hypoglossal MNs
in brainstem slice preparations (Figure 3A) and representative
photomicrograph of fura-2 AM stained HMNs in WT and
(left) and symptomatic SOD1G93A mice (right) shown in
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TABLE 2 | WST-1 cell viability assay in SH-SY5YWT and SH-SY5YG93A cells treated with sodium azide in presence and absence of riluzole and melatonin.
Treatment SH-SY5YWT SH-SY5YG93A P-value
DMEM, 3 min 100 ± 3.42 91 ± 8.67 0.05
DMEM+3 mM Na-azide, 3 min 75 ± 6.34 73.5 ± 6.28 0.01
DMEM+3 mM Na-azide, 30 min 61.25 ± 6.17 54 ± 8.37 0.001
DMEM+3 mM Na-azide+100 µM Riluzole, 3 min 91 ± 4.51 88.25 ± 5.20 0.01
DMEM+3 mM Na-azide+100 µM Melatonin, 3 min 80.25 ± 5.34 78.5 ± 4.19 n.s.
Figure 3B. We evaluated the protective impact of riluzole
on calcium signaling of HMNs of adult WT (Figures 3C,E)
and symptomatic SOD1G93A mice brain stem slices in vitro
(Figures 3D,F). We found that riluzole has a moderate effect
on inhibition of Na-azide (3 mM) induced [Ca2+]i signaling
of MN’s mediated by Na+-azide induced excitotoxicity. At
higher concentration (>50 µM) riluzole moderately inhibited
[Ca2+]i fluorescence in both WT and selectively impaired
HMNs of symptomatic SOD1G93A mice whereas at lower
concentrations (<50 µM) there is no significant effect (data
not shown). Sodium azide-induced mitochondrial [Ca2+]i
release response is significantly different between WT and
symptomatic SOD1G93A mice. The impact of riluzole inhibition
is not specific to only SOD1G93A mice and it also moderately
inhibits [Ca2+]i signaling in WT mice as well (Figure 3;
Table 3).
As illustrated in Figures 3C,D,G; 3 mM Na-azide caused a rise
in the [Ca2+]i transient by mitochondrial complex IV inhibition,
with average peak amplitudes (F/F0) reaching 0.15 ± 0.02 and
0.11 ± 0.01 (Figures 3C,D,G; Table 3) respectively, in HMNs
of adult WT (5 mice/N = 12 slice; n = 58 HMNs) and
symptomatic SOD1G93A mice (5 mice/N = 10 slice; n = 46
HMNs) and subsequently comes to baseline over 2–3 min wash
out with aCSF. In the presence of 100 µM riluzole, application
of 3 mM Na-azide caused a rise in the [Ca2+]i transient, with
average of the peak amplitudes (F/F0) reaching 0.089 ± 0.01
and 0.065 ± 0.01 (Figures 3E–G; Table 3) respectively, in
HMNs of adult WT (6 mice/N = 14 slice; n = 63 HMNs) and
symptomatic SOD1G93A mice (6 mice/N = 13 slice; n = 58
HMNs). The inhibition of the peak amplitude of [Ca2+]i in
SOD1G93A mice (F/F0 = 0.065± 0.01) is prominent compared to
WT mice (F/F0 = 0.089 ± 0.01; P < 0.05, Students two sample
t-test; quantitative fluorescence value compared in Table 3).
The inhibition of [Ca2+]i peak amplitude in SOD1G93A mice
by riluzole might be attributed to a decrease in the entry of
Ca2+ through a voltage dependent calcium channel (VDCC) and
need further investigations. We conclude that riluzole inhibits
Na-azide-induced mitochondrial Ca2+ signaling and it modestly
ameliorate MN degeneration by inhibition of excitotoxicity
trigger by [Ca2+]i eﬄux.
Impact of Riluzole on Metabolic State of
HMNs in Presence of Sodium
Azide-Induced Mitochondrial Respiratory
Chain Inhibition and Excitotoxicity
Mitochondrial ETC associated proton eﬄux causes accumulation
of negative charges in the matrix and electrochemical
gradient across the mitochondrial membrane. Intrinsic NADH
fluorescence in MNs has been shown to serve as a valuable tool to
characterize the metabolic signature of intrinsic energy profiles.
Accordingly, evaluation of intrinsic NADH fluorescence after
inhibition of mitochondrial complex IV with Na-azide indicated
that the mitochondrial respiratory chain was significantly
disturbed in SOD1 G93A animals which is rescues in acute
condition by riluzole by yet unknown mechanism (Figure 4).
To confirm that impact of riluzole on mitochondrial NADH
fluorescence, experiments were performed, in which respiratory
chain activity of HMNs was inhibited by 3 mM Na-azide in
absence (aCSF; Figure 4A) and presence of riluzole (100 µM
riluzole; Figure 4B). Kinetic profile of HMNs (n = 5) NADH
fluorescence in single slice in aCSF (black) and in presence
of riluzole (red) shown in Figure 4C for three consecutive
application.
To analyze the comparative efficiency of mitochondria
of SOD1G93A mice, HMNs were evoked by a 30 mM K+
depolarizing stimulus. When SOD1G93A mice HMNs were
exposed to 30 mM K+ for 20 s, there is immediate and
slow plateau shape decrease in the NADH fluorescence and
subsequently returned to the basal level. To determine whether
the mitochondrial depolarization by 30 mM K+ has any
apparent influence on the lifetime of the NADH fluorescence
and riluzole still rescues HMNs metabolism, 100 µM riluzole was
added to the aCSF superfusate after K+-induced depolarization
(Figures 4D,E). Application of 3 mM Na-azide after 20 s
depolarization induced by K+ resulted in an increase of NADH
fluorescence of 0.024 ± 0.003 and 0.049 ± 0.001 in the presence
of aCSF (N = 5 slice; n= 38 HMNs) and aCSF+100 µM riluzole
(N = 5 slice; n = 41 HMNs), respectively, in SOD1G93A mice
(Figure 4F). Following previous trends there was a slight increase
in the NADH fluorescence in presence of 100 µM riluzole but
there was no significant difference in NADH fluorescence mean
value after 3 mM Na-azide-evoked responses (normalized, F/F0)
post K+-induced depolarization with or without 100µM riluzole.
DISCUSSION
We have shown earlier that [Ca2+]i in HMNs increases in
response to stimulation with mitochondrial electron transport
complex IV inhibitors Na-azide/cyanide and differentially
regulated in WT and SOD1G93A mice and cell culture model
of SOD1 (Bergmann and Keller, 2004; Jaiswal and Keller,
2009; Jaiswal et al., 2009). Given that riluzole and melatonin
has been shown to avert excitotoxicity induced cell death by
various mechanism, including oxidative stress and calcium
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FIGURE 3 | Riluzole induce inhibition of [Ca2+]i in fura-2 AM loaded HMNs exposed to 2 mM Na-azide in adult WT and symptomatic SOD1G93A mice.
(A) A graphical illustration of the adult mouse brainstem slice containing hypoglossal motoneurons (HMNs) marked with black colors [Modified from Jaiswal, 2009.
Optical analysis of [Ca2+]i and mitochondrial signaling pathways: implications for the selective vulnerability of motoneurons in amyotrophic lateral sclerosis (ALS).
Goöttingen, Univ., Diss., 2008. Copyright© 2009 Jaiswal, M. K. ediss.uni-goettingen.de. Used with permission]. (B) A CCD camera images (4 × 4 binning) showing
15 weeks adult WT (left) and symptomatic SOD1 (right) mice HMNs stained with ratiometric calcium dye fura-2 AM (excitation at 360 nm). (C) 3 mM Na-azide was
added in aCSF superfusate and the calcium fluorescence signal was recorded in 14–15 weeks old WT mice HMNs. (D) 3 mM Na-azide was added in aCSF
superfusate and the calcium fluorescence signal was recorded in 14–15 weeks old symptomatic SOD1G93A mice HMNs. (E) 3 mM Na-azide was added in aCSF
superfusate together with 100 µM riluzole and the calcium fluorescence signal was recorded in 14–15 weeks old WT mice HMNs. (F) 3 mM Na-azide was added in
aCSF superfusate together with 100 µM riluzole and the calcium fluorescence signal was recorded in 14–15 weeks old symptomatic SOD1G93A mice HMNs.
Average peak amplitude (gray color) shown as means from 5 to 6 cells in an imaging field (C–F). (G) Bar diagram of effect of 100 µM riluzole on Na-azide induced
blockade of [Ca2+]i measured in adult WT (Light gray) and symptomatic SOD1G93A (Gray sparse) mice HMNs. Data are expressed as means 12 imaging
experiments from five WT mice and corresponding 10 imaging experiments from five symptomatic SOD1G93A mice in acute 3 mM Na-azide experiments. In case of
riluzole experiments, bar diagram represent 14 imaging experiments obtained from six WT mice and corresponding 13 imaging experiments obtained from six
symptomatic SOD1G93A mice. The changes in peak amplitude of [Ca2+]I were calculated as F/F0 (360/390). ∗P < 0.05, ∗∗P < 0.01 compared with adult WT and
symptomatic SOD1G93A mice after riluzole application. Data are expressed as the mean ± SD.
TABLE 3 | Sodium azide-induced mitochondrial [Ca2+]i release and excitotoxicity in absence and presence of riluzole.
Fura-2 fluorescence intensity (F/F0) WT SOD1G93A P-value
3 mM Na-azide 0.15 ± 0.020 0.11 ± 0.018 0.05
3 mM Na-azide+100 µM Riluzole 0.089 ± 0.017 0.065 ± 0.014 0.01
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FIGURE 4 | Impact of riluzole on metabolic state of HMNs measured by NADH fluorescence. (A) Mitochondrial activity of SOD1G93A mice HMNs was
inhibited by 3 mM Na-azide in presence of aCSF. (B) Mitochondrial activity of SOD1G93A mice HMNs was inhibited by 3 mM Na-azide in presence of 100 µM
riluzole. (C) NADH fluorescence intensity profile of HMNs (n = 5) measured in a single slice in aCSF (black) and in presence of riluzole (red) after three consecutive
application of 3 mM Na-azide. Time series experiment for single measurement shown in inset. (D) NADH fluorescence after K+ induced plasma membrane
depolarization and Na-azide-evoked NADH response in HMNs of SOD1G93A mice in presence of aCSF. (E) NADH fluorescence after K+ induced plasma membrane
depolarization and Na-azide-evoked NADH response in HMNs of SOD1G93A mice in presence of 100 µM riluzole. Horizontal black bars indicate the duration of
application of 3 mM Na-azide. The black arrow indicates the 30 mM K+ induced plasma membrane for 30 s. (F) Graphical representation of the effect of 3 mM
Na-azide in presence of aCSF (N = 5 slice; n = 38 HMNs) and 100 µM riluzole (N = 5 slice; n = 41) SOD1G93A mice. The data are expressed as mean ± SD; N,
number of slices/experiments, n, number of cells. ∗p < 0.05.
signaling (Wang, 2009; Mazzone and Nistri, 2011; Jaiswal,
2012; Geevasinga et al., 2016; Gutierrez et al., 2016; Reiter
et al., 2016), inhibition of persistent sodium currents and
Trpm4 (Simard et al., 2012), Trpm4 mediated increase of
Ca2+ influx (Weber et al., 2010) via Ca2+ CRAC and Kca
channels (Dolmetsch and Lewis, 1994), we examined whether
riluzole and melatonin affects mtSOD1-mediated cell death and
excitotoxicity and improve cell survival. Furthermore, since
Na+-azide blocks the mitochondrial ETC in HMNs of ALS,
we further analyzed whether riluzole and melatonin protect
the HMNs from Na-azide induced MN death induced by
excitotoxicity and mediated by inhibition of [Ca2+]mito signaling
cascades. The effect of drug riluzole and melatonin on the
excitotoxicity-induced cell death and [Ca2+]i concentration
induced by mitochondrial blocker was measured, and the
impact of riluzole and melatonin-modulated Ca2+ influx
and Ca2+ release were evaluated. We found that riluzole but
not melatonin, moderately inhibits excitotoxicity-induced
[Ca2+]mito signaling and thereby modestly protects the cell
death in WT and SOD1G93A cell culture model of ALS and
SOD1G93A mice model (Figures 1–3). Previously, it was
shown that melatonin enhance mitochondrial ETC I and
IV and thereby improving mitochondrial respiration, ATP
synthesis and energy metabolism under stress circumstances
(Leon et al., 2005). However, in our experiments melatonin
fail to show neuroprotective action on either cell death
(Figures 1 and 2) or Na+-azide induced [Ca2+]i signaling
(data not shown) in adult WT and corresponding symptomatic
SOD1G93A mice. Our results indicate that the melatonin
mitochondrial neuroprotective action might be governed
by respiratory complex I inhibition or by yet unknown
unidentified mechanism(s). We therefore believe that the
riluzole-targeted inhibition of mitochondrial signaling could
be beneficial in ALS. In this paper, we provide evidence using
three independent methods about inhibition of depolarization-
evoked calcium transients and excitotoxcity in healthy and
diseased MNs and cell death/survival assay in cell culture
model of MNs by neuropharmacological substrates riluzole
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FIGURE 5 | Schematic presentation of the model of mitochondria-mediated sodium-azide induced excitotoxicity inhibition by Riluzole in ALS.
(A) Mitochondrial disturbance and calcium excitotoxicity associated with SOD1 mediated toxicity are predicted to be the key trigger to ALS etiology. The production
of ROS by disturbed mitochondrial metabolism can be readily cytotoxic as ROS can destroy the membrane integrity by averting the specificity of membrane
channels or triggering the opening of particular leaky channels as well as by destroying the lipid components of the membrane. Mitochondrial inhibition additionally
decreases cellular ATP levels, and this further enhances accumulation of intracellular Ca2+. In addition, inhibition of the respiratory chain furthermore decreases the
19m leading to reduced Ca2+ uptake into the mitochondrial matrix and potential release of Ca2+ into the cytoplasm leading to Ca2+ excitotoxicity. Furthermore, it
is also hypothesized and estimated that ROS produced in MNs can escape into the extracellular environment and can damage the glutamate transporters on
astrocytes. (B) An event following a mitochondrial malfunction in MNs inhibits complex IV of the ETC which leads to ROS generation seen in SOD1-mediated toxicity
can be chemically trigger by Na-azide. This phenomenon can be partially reversed by blocking ROS production by riluzole in MNs or by inhibition of Ca2+ efflux at
synapse sites. In addition, ROS generated via mitochondria are mostly neutralized by the inhibition of glutamate release trigger by riluzole. The impact of ROS for the
cell becomes more severe when mitochondria are placed cardinally to buffer the calcium and to control the subsequent metabolic pathways, since an uncontrolled
elevation in the cytosolic Ca2+ can lead to immediate cell death. The observed schematic diagram provide a potential mechanism of how mitochondrial inhibition
can lead to selective MN degeneration and reverse by riluzole.
to protects cells against excitotoxic damage and hence
its therapeutic effects in ALS. These observations may be
relevant to understand the vulnerability of MNs to the
excitotoxic insult that may contribute to the aetiopathology
of ALS.
We found a substantial increase in cell viability and
inhibition of excitotoxicity induced cell death in MNs by
riluzole but not by melatonin (Figures 1 and 2), thus
providing evidence for the efficacy of riluzole in in vitro
transfected cell culture model in the treatment of ALS. Riluzole
has been shown to alleviate neurological symptoms in the
SOD1G93A Tg mouse model of ALS by suppressing oxidative
stress (Seo et al., 2015). Indeed, we observed that riluzole
reduced Na-azide induced and SOD1G93A-mediated cell death
(Figure 1) and increase cell viability (Figure 2) in SH-
SY5YWT and SH-SY5YG93A cells, suggesting that mitochondrial
excitotoxicity and ROS is associated with the mechanism
of SOD1G93A-induced cytotoxicity. However, compared to
riluzole, melatonin fail to prevent Na-azide induced and
SOD1G93A-mediated cell death (Figure 1) and there is no
significant increase in cell viability (Figure 2) in SH-SY5YWT
and SH-SY5YG93A cells, suggesting that mechanism of cell
death protection by melatonin might adopt different cellular
mechanism as it did not affect cell viability induced by
Na-azide induced ROS generation through mitochondrial
inhibition.
Furthermore, we demonstrated that the inhibition of peak
amplitudes of [Ca2+]i in symptomatic SOD1G93A and adult
WT mice is significant when measured with application of
Na+-azide together with riluzole compared to of Na+-azide
alone (Figure 3, p < 0.05). The overall inhibition of the rise
in peak [Ca2+]i transients in the presence of riluzole after a
Na+-azide application in adult WT and symptomatic SOD1G93A
might be due to the potential inhibition of complex IV and
decrease in the entry of Ca2+ through VDCC. Additionally,
in symptomatic SOD1G93A mice, the presence of riluzole
slightly diminished the Na+-azide induced [Ca2+]mito increase
and delayed the baseline recovery by up to 30–60 s. Our
results therefore indicate that riluzole’s moderate inhibition of
[Ca2+]mito signaling may be because of a partial blockade of
intracellular Ca2+ release from the mitochondria. Our finding
further supports the assumption that the riluzole ameliorates
excitability and Ca2+ signaling and this pathway may have
role in its manifold effects on mitochondria mediated cellular
metabolism in ALS.
NADH fluorescence is a good experimental measure to
monitor the metabolic profile of the MNs. In the intact
HMNs besetting the mitochondria by Na-azide adversely affects
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the production of NADH in the mitochondrial metabolism. Our
data shows slight increase in the NADH fluorescence in presence
of 100µM riluzole compared to aCSF but there was no significant
difference in NADH fluorescence mean value (Figure 4). This
implies that there is a significant mitochondrial metabolism
dysfunction and mitochondria in SOD1G93A mice might not able
to sequester enough calcium after K+-induced depolarization
(dysfunctional Ca2+ accumulation activity) or Na-azide-evoked
release response is hampered in HMNs of SOD1G93A mice.
Overall, our results indicate that the inhibition and
stabilization of Ca2+ transient by riluzole under physiological
situation, e.g., diffusion-restricted and in homeostatically
controlled mitochondrial domains might indeed have numerous
functional advantages (Figure 5). Accordingly, drugs targeting
protection of mitochondrial function and homeostasis could
be useful in various forms of ALS by utilizing multidrug
therapy where combined pharmacological intervention target
different domains of mitochondria and Mito-cycle which
ameliorates excitotoxicity both at the MNs and at the neighboring
cells and most likely prolong survival of ALS patients. Our
experiments promise a limited but effective and methodological
way to test the multiple drugs and their targets most likely
tested with different drug cocktails to check the efficacy of
multi-drug therapy. However, more detailed study allowing
identification of mechanism and molecular targets would be
necessary.
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